LLY vs MRVL: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and Marvell Technology, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-17.
Eli Lilly and Company · Healthcare
$1,179.09
+31.7% upside to fair value
High Conviction
Grade A
High Quality
VS
Marvell Technology, Inc. · Technology
$310.58
-18.5% upside to fair value
Grade D
QuantHub Verdict
LLY has more upside to fair value
(+31.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
MRVL |
| Current Price |
$1,179.09 |
$310.58 |
| Fair Value Estimate |
$1,552.32 |
$253.23 |
| Upside to Fair Value |
+31.7%
|
-18.5%
|
| Market Cap |
$1,110.4B |
$271.7B |
| Forward P/E |
—
|
105.7x
|
| EV / EBITDA |
34.3x
|
59.1x
|
| Price / Sales |
14.6x
|
31.2x
|
| Price / FCF |
77.7x
|
163.2x
|
| Revenue Growth YoY |
+55.5%
|
+27.6%
|
| Gross Margin |
83.5%
|
50.6%
|
| Operating Margin |
45.9%
|
16.2%
|
| Return on Equity |
101.3%
|
16.8%
|
| Dividend Yield |
0.55% |
0% |
| FCF Yield |
1.29%
|
0.61%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
Eli Lilly is a global biopharma company whose exceptionally profitable cardiometabolic franchises, led by Mounjaro and Zepbound, are driving a high-quality growth phase: revenue rose 55.5% year over year and earnings rose 168.0% year over year in the most recent quarter, while gross, operating, and net margins were 83.5%, 45.9%, and 35.0%, respectively. Business quality is high because tirzepatid…
Marvell Technology, Inc. designs and supplies semiconductor solutions primarily focused on data infrastructure markets including cloud, AI, carrier 5G, and custom silicon. The company benefits from a narrow but widening moat driven by strong IP and hyperscaler relationships, led by an experienced CEO with a track record of transformational M&A. Despite strong revenue growth of 42% year-over-year …
Accumulation Zones
| Metric |
LLY |
MRVL |
| Zone Low |
$1,164.24 |
$189.92 |
| Zone High |
$1,319.47 |
$215.25 |
| In Buy Zone? |
Yes
|
No
|